Matrix

Centaur Labs specializes in medical data annotation services, aimed at enhancing medical decision-making and diagnostics. The company utilizes a platform that connects a global network of students and professionals, who compete to provide high-quality data labeling. This collaborative model ensures exceptional accuracy and scalability in annotating medical and scientific data. By analyzing medical cases and labeling data effectively, Centaur Labs contributes to the development of advanced medical AI technologies, ultimately helping patients achieve better healthcare outcomes while potentially reducing costs.

D3 Bio, established in 2020, is a biotechnology company headquartered in China. It specializes in the development and registration of innovative medicines within the fields of oncology and immunology. The company's approach involves analyzing clinical and market data to identify gaps in current treatments, employing unique drug development methods targeting new disease pathways and delivery routes, with the ultimate goal of providing patients with novel and effective therapy options.

GRIT Biotechnology is a research and development company based in Shanghai, China, focusing on tumor infiltration lymphocytes (TIL) immunotherapy for the treatment of solid tumors. Founded in 2019, the company is dedicated to advancing the field of immunotherapy with the aim of enhancing the effectiveness of tumor treatments. By leveraging innovative approaches in TIL technology, GRIT Biotechnology seeks to provide new therapeutic options for patients battling solid tumors.

Ucello Therapeutics focuses on the development of allogeneic cell therapies utilizing its proprietary CAR-T cell technology platform, known as CBT-X20. The company aims to create universal CAR-T cell therapeutic drugs that address unmet clinical needs in cancer treatment. By leveraging advanced gene and cell therapy technologies, Ucello's therapies target cancer cells at the molecular level, making them accessible to patients with varying lymphocyte levels and those with a history of transplant relapse. This innovative approach allows for effective cancer gene therapies to be administered to individuals with specific pre-existing medical conditions.

Zenshine Pharma is a clinical-stage biopharmaceutical company with a focus on the development of small molecule drugs for cancer, viral infections, and autoimmune diseases.

Ouli Biomedical is a pharmaceutical company. They offer nucleic acid drug discovery, laboratory research and development, process and analysis development, CMC services, API production, and drug registration.

Levostar is a biotechnology company focused on the development and manufacture of cell and gene therapy products. It provides innovative technologies and comprehensive solutions for the cell gene therapy industry. The company offers clinical testing services for various therapy platforms, including viral vector platforms and mRNA vaccines. Additionally, Levostar specializes in Good Manufacturing Practice (GMP)-level production processes and quality control methods for plasmids and mRNAs. By delivering these services and products, Levostar aims to accelerate research and development in gene cell therapy and mRNA drug development, contributing to advancements in the biotechnological field.

Insyce creates equipment and apparatus for science. Its business strives to provide tools and technology for bio labs that monitor the environment to deliver accurate data and speedy chemical analysis while keeping lab costs down for their clients. It is dedicated to providing upper biological separation equipment and chemical analysis tools for global clients, cutting down on client operating expenses, and adding value for clients.

Rgenta Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of RNA-targeting medicines with a primary focus on oncology and neurological disorders. Founded in 2018, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This platform enables the design of small-molecule compounds that modulate interactions among the spliceosome, regulatory proteins, and RNAs. By unlocking the therapeutic potential of previously undruggable targets, Rgenta aims to create oral, small-molecule therapies that address critical needs in human disease treatment, particularly in the realm of cancer.

Wanzhong Yixin Biotechnology is a developer of semiconductor integrated circuit biosensor chips and other related devices. The company's biosensor chip products are used in emerging fields such as genetic testing, water quality monitoring, and environmental protection IoT monitoring.

Yudo Bio provides biopharmaceutical products. It has its headquarters in Shanghai in China.

Nutshell Therapeuticstein drug discovery platform, composed of a well-integrated set of computational modules and experimental tools based on a proprietary AI algorithm and deep know-how derived from biochemistry and biophysics, possesses the capability to discover a host of drug entities, including various types of protein activators and subtype/mutation-selective small molecules.

Lingyi Biology is a gene therapy company that uses a platform to validate the functionality of animal models of rare diseases. It is dedicated to sourcing innovation, with a focus on genetic rare diseases like metabolism, CNS, and ophthalmology. Lingyi Biology has a gene therapy and rare disease discovery, development, and industrialization team, as well as a rare disease animal model preparation and verification platform, to address the pain point of a lack of effective animal models for rare disease research and development.

Ucello Therapeutics focuses on the development of allogeneic cell therapies utilizing its proprietary CAR-T cell technology platform, known as CBT-X20. The company aims to create universal CAR-T cell therapeutic drugs that address unmet clinical needs in cancer treatment. By leveraging advanced gene and cell therapy technologies, Ucello's therapies target cancer cells at the molecular level, making them accessible to patients with varying lymphocyte levels and those with a history of transplant relapse. This innovative approach allows for effective cancer gene therapies to be administered to individuals with specific pre-existing medical conditions.

Vibrant develops an AI drug development platform to focus on building immune system-related drug pipelines. The company will use artificial intelligence algorithms to accelerate the efficiency of drug development in various aspects such as target discovery, drug design, and drug efficacy evaluation; at the same time, the company expects to continuously improve the success rate of drug development through sustainable data accumulation and algorithm optimization. It was founded and headed by Dr. Wang Luquan and is based in Guangzhou, Guangdong, China.

Protoga is a biotechnology company specializing in the development and commercialization of microalgae-based products aimed at enhancing human immunity. The firm focuses on large-scale microalgae cultivation and offers contract development and manufacturing organization (CDMO) services. Protoga's products are meticulously cultivated and processed to ensure high quality and consistency, incorporating beneficial compounds such as β-1,3-Glucan, microalgal protein, DHA, and astaxanthin. The company's customer base spans various industries, including food, healthcare, and cosmetics, reflecting its commitment to providing innovative solutions derived from microalgae biosynthesis technology.

KYinno is a drug development company that is dedicated to oncology drug development with a focus on immune treatments against cancer.

NeuraMatrix is a developer of advanced brain-computer interface technology that focuses on enhancing human-computer interaction through a comprehensive hardware-software platform. The company aims to facilitate research in brain science and neurological diseases, offering innovative solutions for diagnosis, treatment, and drug development. NeuraMatrix recently secured substantial funding to support its initiatives, which will be allocated toward upgrading research and development equipment, mass production of chips, product iterations, and market promotion. By leveraging its technology, NeuraMatrix seeks to unlock significant commercial applications in the field of neuroscience and improve the integration of users with technological systems.

Zhongke Guosheng is research and development firm that designs and manufactures furan-based bio-based materials.

Insyce creates equipment and apparatus for science. Its business strives to provide tools and technology for bio labs that monitor the environment to deliver accurate data and speedy chemical analysis while keeping lab costs down for their clients. It is dedicated to providing upper biological separation equipment and chemical analysis tools for global clients, cutting down on client operating expenses, and adding value for clients.

Excell Biology is dedicated to addressing the biomedical industry's blockage and accomplishing the localization of essential raw materials. It offers customers biological medicine, cell, and gene therapy, and fundamental scientific research products and services of the quality and concentrates on three product sectors, including serum-free medium, fetal bovine serum, and identification reagents.

Joes Future Food engages the development, production, testing, and sales of raw and auxiliary materials for food and biological products.

RootPath Genomics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in developing a personalized T-cell therapy platform that integrates precision medicine with cancer immunotherapy. The company's innovative technologies focus on the analysis and manipulation of individual immune cells, enabling advancements in immune and cell therapy. By precisely monitoring and modulating the immune system, RootPath aims to enhance the diagnosis and treatment of cancer, contributing to significant improvements in patient outcomes.

Centaur Labs specializes in medical data annotation services, aimed at enhancing medical decision-making and diagnostics. The company utilizes a platform that connects a global network of students and professionals, who compete to provide high-quality data labeling. This collaborative model ensures exceptional accuracy and scalability in annotating medical and scientific data. By analyzing medical cases and labeling data effectively, Centaur Labs contributes to the development of advanced medical AI technologies, ultimately helping patients achieve better healthcare outcomes while potentially reducing costs.

DP Technology is a global leader in the "AI for Science" research paradigm, where AI learns scientific principles and data, then tackles key challenges in scientific research and industrial R&D. DP's commitment to interdisciplinary research has led to the creation of the DP "Particle Universe", an array of pre-trained large science models designed to bridge foundational research with practical industrial applications. DP's software suite includes the Bohrium® Scientific Research Space, Hermite® Computational Drug Design Platform, RiDYMO® Dynamics Platform, and Piloteye® Battery Design Automation Platform. Together, these platforms form a robust foundation for industrial innovation and an open ecosystem for AI in science, fostering advancements in key areas such as drug discovery, energy, material science, and information technology.

Scivita Medical is a technology-focused enterprise specializing in optical diagnosis and treatment, as well as the development of multidimensional imaging and high-performance materials for minimally invasive medical procedures. The company offers a range of products, including flexible and rigid endoscopes, designed to enhance the capabilities of medical professionals. Its product lineup features advanced technologies such as ultra-high-definition visualization, 3D imaging, and fluorescence visualization, which facilitate precise diagnostics and treatments. Key offerings include a 4K medical endoscope camera system, integrated 4K-3D endoscope systems, and various single-use endoscopic devices for applications in gynecology, urology, and pulmonology. Scivita Medical aims to provide doctors with innovative tools that improve patient outcomes through enhanced visualization and minimally invasive techniques.

Bota Biosciences is a global industrial biotechnology company based in Hangzhou, China, founded in 2019. The company specializes in synthetic bioengineering technology for bio-manufacturing, focusing on developing efficient, eco-friendly, and cost-effective solutions. Bota Biosciences has created an integrative bioengineering platform that connects biological design to scale-up manufacturing, facilitating the transition to sustainable living. It operates its own pilot plant and manufacturing facility, which enhances its capacity to offer scalable industrial solutions and market-ready products across various sectors, including nutrition, food, personal care, and animal health. With a dynamic and multidisciplinary team, Bota Biosciences aims to channel biotechnology innovations for a global impact. The company has successfully raised substantial funding, exceeding $145 million, with investments from several prominent strategic and financial backers.

Jyss Bio is a developer of disposable bioreactors and peripheral equipment.

PAQ Therapeutics is a biotechnology company focused on restoring health and curing diseases by harnessing autophagy, the body's natural process for cellular degradation. The company develops a novel class of small-molecule degraders using autophagosome-tethering compound technology. This innovative approach allows these compounds to bind a diverse array of substrates to the autophagy pathway, enabling healthcare providers to create effective treatments for serious diseases where traditional therapeutic options are often limited. Through its research and development efforts, PAQ Therapeutics aims to provide new solutions for patients in need of advanced medical therapies.

GRIT Biotechnology is a research and development company based in Shanghai, China, focusing on tumor infiltration lymphocytes (TIL) immunotherapy for the treatment of solid tumors. Founded in 2019, the company is dedicated to advancing the field of immunotherapy with the aim of enhancing the effectiveness of tumor treatments. By leveraging innovative approaches in TIL technology, GRIT Biotechnology seeks to provide new therapeutic options for patients battling solid tumors.

Nutshell Therapeuticstein drug discovery platform, composed of a well-integrated set of computational modules and experimental tools based on a proprietary AI algorithm and deep know-how derived from biochemistry and biophysics, possesses the capability to discover a host of drug entities, including various types of protein activators and subtype/mutation-selective small molecules.

Megarobo is an AI and robotics company established in 2016 and headquartered in Beijing, China. It specializes in developing collaborative robots and advanced automation solutions tailored for life sciences, clinical diagnosis, and applied chemistry. By focusing on integrating robotics and artificial intelligence into industry applications, Megarobo aims to enhance research efficiency for life science companies and scientific research institutions. The company is dedicated to providing flexible and practical automation products that streamline laboratory services, ultimately driving innovation in the field of scientific research.

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and located in Wilmington, Delaware. The company is dedicated to discovering and developing innovative small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. By employing a discovery approach that leverages target structure biology and structure-based drug design, NiKang Therapeutics aims to facilitate the rapid and efficient development of proprietary drug candidates with optimal pharmacological properties. The company seeks to enhance the treatment options available to healthcare providers, ultimately improving patient outcomes in the fight against cancer.

Jyss Bio is a developer of disposable bioreactors and peripheral equipment.

Scivita Medical is a technology-focused enterprise specializing in optical diagnosis and treatment, as well as the development of multidimensional imaging and high-performance materials for minimally invasive medical procedures. The company offers a range of products, including flexible and rigid endoscopes, designed to enhance the capabilities of medical professionals. Its product lineup features advanced technologies such as ultra-high-definition visualization, 3D imaging, and fluorescence visualization, which facilitate precise diagnostics and treatments. Key offerings include a 4K medical endoscope camera system, integrated 4K-3D endoscope systems, and various single-use endoscopic devices for applications in gynecology, urology, and pulmonology. Scivita Medical aims to provide doctors with innovative tools that improve patient outcomes through enhanced visualization and minimally invasive techniques.

Advaccine is a biotechnology company dedicated to the discovery and development of innovative vaccines aimed at addressing unmet clinical needs globally. The company specializes in both preventive and therapeutic vaccines, with a research pipeline that includes first-in-class candidates for diseases such as hepatitis B, respiratory syncytial virus, type 1 diabetes, and coronavirus. By focusing on viral vaccine technology, Advaccine aims to provide effective treatments and improve health outcomes for patients, particularly those with chronic conditions like diabetes.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on xenotransplantation. The company aims to address the critical shortage of organ donors by utilizing advanced gene editing techniques to develop safe and effective cells, tissues, and organs for human transplantation. Their mission is to eliminate the waiting period associated with organ transplants, providing patients with access to life-saving organs. By harnessing cutting-edge genetic editing technology, Qihan Biotech seeks to create viable organs that can be transplanted into humans, thereby contributing to a solution for the global organ donor crisis.

NovoCodex is involved in the research, development, and manufacture of biological products. Its mission is to provide cutting-edge technology to meet clinical needs. In Binhai New City Science and Technology Park, the company has established a biopharmaceutical laboratory with experience and capabilities in genetic engineering construction, cell culture, toxin synthesis, ADC coupling, preparation filling, preclinical research, and clinical research.

NeuraMatrix is a developer of advanced brain-computer interface technology that focuses on enhancing human-computer interaction through a comprehensive hardware-software platform. The company aims to facilitate research in brain science and neurological diseases, offering innovative solutions for diagnosis, treatment, and drug development. NeuraMatrix recently secured substantial funding to support its initiatives, which will be allocated toward upgrading research and development equipment, mass production of chips, product iterations, and market promotion. By leveraging its technology, NeuraMatrix seeks to unlock significant commercial applications in the field of neuroscience and improve the integration of users with technological systems.

Megarobo is an AI and robotics company established in 2016 and headquartered in Beijing, China. It specializes in developing collaborative robots and advanced automation solutions tailored for life sciences, clinical diagnosis, and applied chemistry. By focusing on integrating robotics and artificial intelligence into industry applications, Megarobo aims to enhance research efficiency for life science companies and scientific research institutions. The company is dedicated to providing flexible and practical automation products that streamline laboratory services, ultimately driving innovation in the field of scientific research.

Senti Bio, established in 2016 and headquartered in South San Francisco, specializes in synthetic biotechnology for therapeutic development. The company's core focus is engineering gene circuits, a platform technology that enables precise control over cellular behavior. Senti Bio's innovative approach allows for the creation of therapies with enhanced specificity and control, particularly in oncology. Their product pipeline includes SENTI-202, an off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells while sparing healthy bone marrow, and SENTI-301A, a treatment for hepatocellular carcinoma.

Joes Future Food engages the development, production, testing, and sales of raw and auxiliary materials for food and biological products.

nference, Inc. is a biotechnology company that specializes in an AI-based software platform designed to synthesize and analyze biomedical information. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference focuses on transforming unstructured and structured data from biomedical literature, electronic medical records, and real-world datasets. The company's technology utilizes neural networks to automate the extraction of insights from diverse datasets, facilitating advancements in drug discovery, life cycle management, and precision medicine. By providing comprehensive biological and clinical insights, nference aims to support pharmaceutical, biotechnology, and healthcare enterprises in overcoming challenges in drug development and clinical research, ultimately enabling the discovery of personalized diagnostics and treatments for patients.

Nuance Biotech Inc. is a pharmaceutical development company based in Shanghai, China, founded in 2014. The company focuses on the research and development of innovative drug formulations, offering products in the form of capsules, injections, and tubes. In addition to its core pharmaceutical development activities, Nuance Biotech also provides commercial and academic platforms for drug-related ventures and offers contract sales organization services. Through its diverse capabilities, the company aims to advance healthcare solutions and contribute to the pharmaceutical industry.

Tallac Therapeutics is a biopharmaceutical company based in Burlingame, California, focused on developing innovative immunotherapies for cancer patients. Established in 2018, the company specializes in creating conjugates of antibodies combined with potent toll-like receptor agonists. This approach aims to activate the immune system in a targeted manner, enhancing both innate and adaptive immunity to effectively combat various solid tumor malignancies. By providing advanced treatment options, Tallac Therapeutics seeks to improve patient outcomes in the fight against cancer.

GRIT Biotechnology is a research and development company based in Shanghai, China, focusing on tumor infiltration lymphocytes (TIL) immunotherapy for the treatment of solid tumors. Founded in 2019, the company is dedicated to advancing the field of immunotherapy with the aim of enhancing the effectiveness of tumor treatments. By leveraging innovative approaches in TIL technology, GRIT Biotechnology seeks to provide new therapeutic options for patients battling solid tumors.

Beijing Biostar Technologies, Ltd., established in 2002, is a Chinese biopharmaceutical company based in Beijing. It specializes in the development of anti-tumor chemotherapy biopharmaceutical molecules, with a focus on creating innovative small molecule chemical drugs for cancer treatment. The company, led by a team of Chinese scientists previously based in the United States, including Dr. Tang Li and Dr. Qiu Rongguo, aims to advance its technology to an international level.

D3 Bio, established in 2020, is a biotechnology company headquartered in China. It specializes in the development and registration of innovative medicines within the fields of oncology and immunology. The company's approach involves analyzing clinical and market data to identify gaps in current treatments, employing unique drug development methods targeting new disease pathways and delivery routes, with the ultimate goal of providing patients with novel and effective therapy options.

GeneCast Biotechnology Co., Ltd. is a Beijing-based company founded in 2014 that specializes in gene research and the development of advanced cancer diagnostic solutions. The company offers a technology platform for cell-free DNA next-generation sequencing (NGS) tests, which are used for companion diagnostics, genetic profiling, prognosis, and monitoring of various solid tumors, including lung, colorectal, liver, and breast cancers. GeneCast provides non-invasive and precise tumor diagnoses and personalized treatment guidance, leveraging high-throughput sequencing and bioinformatics. The company collaborates with hospitals and research institutions to enhance cancer treatment and genetic testing, aiming to improve patient outcomes and quality of life. GeneCast is also focused on advancing its research and clinical trials while expanding its distribution channels.

Advaccine is a biotechnology company dedicated to the discovery and development of innovative vaccines aimed at addressing unmet clinical needs globally. The company specializes in both preventive and therapeutic vaccines, with a research pipeline that includes first-in-class candidates for diseases such as hepatitis B, respiratory syncytial virus, type 1 diabetes, and coronavirus. By focusing on viral vaccine technology, Advaccine aims to provide effective treatments and improve health outcomes for patients, particularly those with chronic conditions like diabetes.

TaiMei Technology is a digital innovator specializing in the research and development sector of the life sciences industry. The company has created a comprehensive digital platform that facilitates clinical research by offering insights into various stages of drug development, pharmacovigilance, marketing, and market access. By leveraging advanced technologies such as artificial intelligence, big data, cloud computing, and mobile internet, TaiMei provides integrated solutions that support industry stakeholders throughout the entire product life cycle. The platform encompasses a range of functionalities, including clinical data management, medical imaging, trial management, and drug monitoring, all aimed at enhancing clinical research efficiency. Ultimately, TaiMei Technology is focused on building the future infrastructure of the life sciences industry to expedite product launches, improve drug safety, and enhance accessibility for patients and healthcare providers.

InventisBio Inc. is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and metabolic diseases. Founded in 2013 and based in Pudong, China, the company specializes in targeted therapies, particularly for lung cancer, breast cancer, and gout. Its product pipeline includes small molecule drug candidates, such as D-0316, a third-generation EGFR-T790M tyrosine kinase inhibitor. InventisBio is also engaged in developing novel immuno-oncology therapies that can be used in conjunction with existing treatments like PD-1 antibodies for various cancer types. The company was co-founded by Dr. Yaolin Wang and other scientists with extensive experience in drug discovery at leading pharmaceutical firms, focusing on significant health challenges such as tumors and metabolic disorders.

Bota Biosciences is a global industrial biotechnology company based in Hangzhou, China, founded in 2019. The company specializes in synthetic bioengineering technology for bio-manufacturing, focusing on developing efficient, eco-friendly, and cost-effective solutions. Bota Biosciences has created an integrative bioengineering platform that connects biological design to scale-up manufacturing, facilitating the transition to sustainable living. It operates its own pilot plant and manufacturing facility, which enhances its capacity to offer scalable industrial solutions and market-ready products across various sectors, including nutrition, food, personal care, and animal health. With a dynamic and multidisciplinary team, Bota Biosciences aims to channel biotechnology innovations for a global impact. The company has successfully raised substantial funding, exceeding $145 million, with investments from several prominent strategic and financial backers.

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and located in Wilmington, Delaware. The company is dedicated to discovering and developing innovative small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. By employing a discovery approach that leverages target structure biology and structure-based drug design, NiKang Therapeutics aims to facilitate the rapid and efficient development of proprietary drug candidates with optimal pharmacological properties. The company seeks to enhance the treatment options available to healthcare providers, ultimately improving patient outcomes in the fight against cancer.

Rgenta Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of RNA-targeting medicines with a primary focus on oncology and neurological disorders. Founded in 2018, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This platform enables the design of small-molecule compounds that modulate interactions among the spliceosome, regulatory proteins, and RNAs. By unlocking the therapeutic potential of previously undruggable targets, Rgenta aims to create oral, small-molecule therapies that address critical needs in human disease treatment, particularly in the realm of cancer.

nference, Inc. is a biotechnology company that specializes in an AI-based software platform designed to synthesize and analyze biomedical information. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference focuses on transforming unstructured and structured data from biomedical literature, electronic medical records, and real-world datasets. The company's technology utilizes neural networks to automate the extraction of insights from diverse datasets, facilitating advancements in drug discovery, life cycle management, and precision medicine. By providing comprehensive biological and clinical insights, nference aims to support pharmaceutical, biotechnology, and healthcare enterprises in overcoming challenges in drug development and clinical research, ultimately enabling the discovery of personalized diagnostics and treatments for patients.

RootPath Genomics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in developing a personalized T-cell therapy platform that integrates precision medicine with cancer immunotherapy. The company's innovative technologies focus on the analysis and manipulation of individual immune cells, enabling advancements in immune and cell therapy. By precisely monitoring and modulating the immune system, RootPath aims to enhance the diagnosis and treatment of cancer, contributing to significant improvements in patient outcomes.

Lansion Biotechnology is specialized in research & development, production, sell, services of in vitro diagnostic reagents and devices. With its advanced technology concept, Lansionbio provides equioment, reagents and services to world-wild clients according to their needs.

GeneCast Biotechnology Co., Ltd. is a Beijing-based company founded in 2014 that specializes in gene research and the development of advanced cancer diagnostic solutions. The company offers a technology platform for cell-free DNA next-generation sequencing (NGS) tests, which are used for companion diagnostics, genetic profiling, prognosis, and monitoring of various solid tumors, including lung, colorectal, liver, and breast cancers. GeneCast provides non-invasive and precise tumor diagnoses and personalized treatment guidance, leveraging high-throughput sequencing and bioinformatics. The company collaborates with hospitals and research institutions to enhance cancer treatment and genetic testing, aiming to improve patient outcomes and quality of life. GeneCast is also focused on advancing its research and clinical trials while expanding its distribution channels.

Ansun Biopharma, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative therapies to prevent and treat serious human diseases. The company specializes in host-directed anti-viral therapies, which aim to combat respiratory viral infections, including various strains of influenza and parainfluenza viruses. Its lead product candidates include Fludase, designed for the prophylaxis and treatment of respiratory infections, and Viradin, an intravenous therapeutic for sepsis and viral hemorrhagic fevers caused by pathogens such as Ebola and Marburg viruses. Additionally, Ansun Biopharma has developed TOSAP, a formulation technology for drug delivery using microspheres and nanospheres. Founded in 2003, the company was previously known as NexBio, Inc. before rebranding in 2011.

Chameleon Biosciences Inc. specializes in developing gene therapy solutions using Adeno Associated Virus (AAV) technology to address rare genetic diseases. Founded in 2017 and based in San Anselmo, California, the company focuses on delivering therapeutic proteins to targeted tissues while minimizing immune responses to enhance gene delivery and reduce immunogenicity. Chameleon aims to transform the treatment landscape for genetic disorders, particularly in infants, where a significant percentage of fatalities are attributed to these conditions. The company is dedicated to ensuring that affected children receive accurate, lower-dose treatments that can be administered multiple times as needed. By masking foreign proteins and shielding the viral capsid from antibodies, Chameleon seeks to increase the range of diseases that can be treated effectively, thereby improving patient outcomes and quality of life.

Chemclin Biotech is a Chinese technical service provider specializing in in-vitro diagnostic instruments and auxiliary reagents for clinical diagnosis. The company develops, produces, and sells clinical immunochemiluminescence diagnostic testing reagents and instruments. Its services encompass a range of clinical inspection instruments, including chemiluminescence and biochemical reagents, as well as technical support, management, and certification. Additionally, Chemclin operates independent medical laboratories and is focused on introducing innovative diagnostic products and services to the Chinese market.

Si'ao Biotechnology engages in the development and production of genetic engineering vaccines and test kits.

GrandOmics is a company that specializes in molecular diagnosis, research, and carrier screening for single-gene diseases. It offers comprehensive genetic testing services that are both scientific and accurate. The company has developed GrandBox, a suite of software designed for clinical sample management and data analysis, which facilitates the management and visualization of genetic disease sequencing data. GrandOmics employs single-molecule, real-time sequencing technology to enhance disease detection and provides a one-stop clinical data analysis platform for laboratories, ensuring efficient and precise data management in genetic research.

Adlai Nortye Biopharma Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative cancer therapies and treatments for metabolic diseases. Founded in 2004 and based in Hangzhou, China, the company has established research and development and clinical operations in both China and the United States. Adlai Nortye has a diverse pipeline of over ten drug candidates, including several in various stages of clinical development, such as buparlisib (AN2025), palupiprant (AN0025), and AN4005, alongside preclinical candidates like AN8025, AN9025, and AN1025. The company emphasizes collaborations and internal discoveries to advance its strategic focus on oncology.

nference, Inc. is a biotechnology company that specializes in an AI-based software platform designed to synthesize and analyze biomedical information. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference focuses on transforming unstructured and structured data from biomedical literature, electronic medical records, and real-world datasets. The company's technology utilizes neural networks to automate the extraction of insights from diverse datasets, facilitating advancements in drug discovery, life cycle management, and precision medicine. By providing comprehensive biological and clinical insights, nference aims to support pharmaceutical, biotechnology, and healthcare enterprises in overcoming challenges in drug development and clinical research, ultimately enabling the discovery of personalized diagnostics and treatments for patients.

Ansun Biopharma, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative therapies to prevent and treat serious human diseases. The company specializes in host-directed anti-viral therapies, which aim to combat respiratory viral infections, including various strains of influenza and parainfluenza viruses. Its lead product candidates include Fludase, designed for the prophylaxis and treatment of respiratory infections, and Viradin, an intravenous therapeutic for sepsis and viral hemorrhagic fevers caused by pathogens such as Ebola and Marburg viruses. Additionally, Ansun Biopharma has developed TOSAP, a formulation technology for drug delivery using microspheres and nanospheres. Founded in 2003, the company was previously known as NexBio, Inc. before rebranding in 2011.

TaiMei Technology is a digital innovator specializing in the research and development sector of the life sciences industry. The company has created a comprehensive digital platform that facilitates clinical research by offering insights into various stages of drug development, pharmacovigilance, marketing, and market access. By leveraging advanced technologies such as artificial intelligence, big data, cloud computing, and mobile internet, TaiMei provides integrated solutions that support industry stakeholders throughout the entire product life cycle. The platform encompasses a range of functionalities, including clinical data management, medical imaging, trial management, and drug monitoring, all aimed at enhancing clinical research efficiency. Ultimately, TaiMei Technology is focused on building the future infrastructure of the life sciences industry to expedite product launches, improve drug safety, and enhance accessibility for patients and healthcare providers.

23Mofang specializes in genetic testing services tailored for the Chinese population and engages in life data analysis. The company develops saliva-based testing kits that allow users to evaluate their ancestral origins, genetic risks, and traits. By analyzing samples, 23Mofang provides detailed reports through a mobile application, empowering individuals and families to proactively manage potential health issues. Additionally, the company aims to create a comprehensive database of life data, aligning with its mission to enhance the well-being of its users through reliable and accessible genetic information.

GeneCast Biotechnology Co., Ltd. is a Beijing-based company founded in 2014 that specializes in gene research and the development of advanced cancer diagnostic solutions. The company offers a technology platform for cell-free DNA next-generation sequencing (NGS) tests, which are used for companion diagnostics, genetic profiling, prognosis, and monitoring of various solid tumors, including lung, colorectal, liver, and breast cancers. GeneCast provides non-invasive and precise tumor diagnoses and personalized treatment guidance, leveraging high-throughput sequencing and bioinformatics. The company collaborates with hospitals and research institutions to enhance cancer treatment and genetic testing, aiming to improve patient outcomes and quality of life. GeneCast is also focused on advancing its research and clinical trials while expanding its distribution channels.

Qrativ, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in developing an AI-driven healthcare platform, known as Darwin.ai, which focuses on identifying new treatments for rare diseases with unmet medical needs. By leveraging machine learning and artificial intelligence, Qrativ's drug purposing platform facilitates the discovery and development of new uses for existing molecules, aiming to provide patients with access to treatments that are currently unavailable in the market. The company collaborates with biotechnology and pharmaceutical firms to enhance their research and development efforts in addressing these critical healthcare challenges.

Nuance Biotech Inc. is a pharmaceutical development company based in Shanghai, China, founded in 2014. The company focuses on the research and development of innovative drug formulations, offering products in the form of capsules, injections, and tubes. In addition to its core pharmaceutical development activities, Nuance Biotech also provides commercial and academic platforms for drug-related ventures and offers contract sales organization services. Through its diverse capabilities, the company aims to advance healthcare solutions and contribute to the pharmaceutical industry.

TaiMei Technology is a digital innovator specializing in the research and development sector of the life sciences industry. The company has created a comprehensive digital platform that facilitates clinical research by offering insights into various stages of drug development, pharmacovigilance, marketing, and market access. By leveraging advanced technologies such as artificial intelligence, big data, cloud computing, and mobile internet, TaiMei provides integrated solutions that support industry stakeholders throughout the entire product life cycle. The platform encompasses a range of functionalities, including clinical data management, medical imaging, trial management, and drug monitoring, all aimed at enhancing clinical research efficiency. Ultimately, TaiMei Technology is focused on building the future infrastructure of the life sciences industry to expedite product launches, improve drug safety, and enhance accessibility for patients and healthcare providers.

TopGene, founded in 2014 and based in Guangzhou, China, specializes in genomics technology for human medicine and life sciences. The company provides a range of genetic testing and molecular diagnostics services aimed at various diseases, including chromosomal disorders, hereditary deafness, and multiple cancer types. Its offerings include next-generation sequencing, DNA/RNA extraction, and targeted resequencing, catering to sectors such as academia, biotechnology, government, and pharmaceuticals. TopGene also emphasizes precision medicine through its integrated services, which combine scientific research with clinical applications to enhance healthcare outcomes. The company serves patients both in China and internationally.

GrandOmics is a company that specializes in molecular diagnosis, research, and carrier screening for single-gene diseases. It offers comprehensive genetic testing services that are both scientific and accurate. The company has developed GrandBox, a suite of software designed for clinical sample management and data analysis, which facilitates the management and visualization of genetic disease sequencing data. GrandOmics employs single-molecule, real-time sequencing technology to enhance disease detection and provides a one-stop clinical data analysis platform for laboratories, ensuring efficient and precise data management in genetic research.

TaiMei Technology is a digital innovator specializing in the research and development sector of the life sciences industry. The company has created a comprehensive digital platform that facilitates clinical research by offering insights into various stages of drug development, pharmacovigilance, marketing, and market access. By leveraging advanced technologies such as artificial intelligence, big data, cloud computing, and mobile internet, TaiMei provides integrated solutions that support industry stakeholders throughout the entire product life cycle. The platform encompasses a range of functionalities, including clinical data management, medical imaging, trial management, and drug monitoring, all aimed at enhancing clinical research efficiency. Ultimately, TaiMei Technology is focused on building the future infrastructure of the life sciences industry to expedite product launches, improve drug safety, and enhance accessibility for patients and healthcare providers.

TaiMei Technology is a digital innovator specializing in the research and development sector of the life sciences industry. The company has created a comprehensive digital platform that facilitates clinical research by offering insights into various stages of drug development, pharmacovigilance, marketing, and market access. By leveraging advanced technologies such as artificial intelligence, big data, cloud computing, and mobile internet, TaiMei provides integrated solutions that support industry stakeholders throughout the entire product life cycle. The platform encompasses a range of functionalities, including clinical data management, medical imaging, trial management, and drug monitoring, all aimed at enhancing clinical research efficiency. Ultimately, TaiMei Technology is focused on building the future infrastructure of the life sciences industry to expedite product launches, improve drug safety, and enhance accessibility for patients and healthcare providers.

nference, Inc. is a biotechnology company that specializes in an AI-based software platform designed to synthesize and analyze biomedical information. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference focuses on transforming unstructured and structured data from biomedical literature, electronic medical records, and real-world datasets. The company's technology utilizes neural networks to automate the extraction of insights from diverse datasets, facilitating advancements in drug discovery, life cycle management, and precision medicine. By providing comprehensive biological and clinical insights, nference aims to support pharmaceutical, biotechnology, and healthcare enterprises in overcoming challenges in drug development and clinical research, ultimately enabling the discovery of personalized diagnostics and treatments for patients.

ETComm is a biotechnology firm focused on developing innovative digital health products for hospitals and community medical services. The company offers a smart medical service solution that serves as a health gatekeeper, seamlessly linking various types of electronic medical devices without requiring user operation. Their product lineup includes a digital electrocardiograph, a body fat measurement instrument, and a Bluetooth blood pressure monitor, all designed to enhance patient health management. Additionally, ETComm provides community members with direct health product OEM services, technical support, and background data analysis, ensuring comprehensive support for medical practitioners and improving overall healthcare outcomes.

ET Healthcare, Inc. is an in vitro diagnostics company that specializes in manufacturing central laboratory analyzers for both inpatient and outpatient testing in various hospital settings, including pediatric care, intensive care units, and emergency rooms. The company has developed the Pylon Immunochemistry System, which integrates laboratory analysis with point-of-care testing to meet diverse immunodiagnostic needs, such as inflammation, cardiac function, fertility, infectious diseases, and tumor detection. Additionally, the Pylon BNP Immunoassay supports heart failure management by measuring B-type natriuretic peptide levels in plasma. ET Healthcare's products aim to bring the performance of traditional central lab analyzers to near-patient settings, addressing requirements for space, plumbing, and staffing. Headquartered in Palo Alto, California, the company also has offices in Shanghai and manufacturing facilities in Suzhou, China.

GeneDock, founded in September 2014, is a national high-tech enterprise specializing in precision medical data technology. The company develops and provides a comprehensive SaaS platform that allows users to extract, analyze, and visualize medical records, facilitating improved research and studies for medical and scientific institutions. With industry-leading expertise, GeneDock has successfully built data platforms for numerous prominent facilities, including top three hospitals and leading industry organizations in China. The core team comprises members with backgrounds from renowned companies, and the firm has attracted investment from notable institutions. GeneDock aims to drive innovation in healthcare through advanced data technology solutions.

ET Healthcare, Inc. is an in vitro diagnostics company that specializes in manufacturing central laboratory analyzers for both inpatient and outpatient testing in various hospital settings, including pediatric care, intensive care units, and emergency rooms. The company has developed the Pylon Immunochemistry System, which integrates laboratory analysis with point-of-care testing to meet diverse immunodiagnostic needs, such as inflammation, cardiac function, fertility, infectious diseases, and tumor detection. Additionally, the Pylon BNP Immunoassay supports heart failure management by measuring B-type natriuretic peptide levels in plasma. ET Healthcare's products aim to bring the performance of traditional central lab analyzers to near-patient settings, addressing requirements for space, plumbing, and staffing. Headquartered in Palo Alto, California, the company also has offices in Shanghai and manufacturing facilities in Suzhou, China.

Nanjing King-friend Biochemical Pharmaceutical is focused on research, production, and sales of raw material medicines of heparin sodium. It mainly produces a series of products including heparin sodium and low molecular heparin. Nanjing King-friend Biochemical Pharmaceutical was restructured and founded in March 2005. As of today, it owns two subsidiaries and two holding subsidiaries and its registered capital is 36 million. Its output of heparin sodium accounts for 20% of the world’s heparin sodium.